Market Overview:
A radioimmunoassay (RIA) is an immunoassay which makes use of radiolabeled molecules in a sequential process of immunoassay binding. A RIA is an extremely sensitive immunoassay technique employed to measure antibody concentrations (such as hormone levels in plasma) using antibodies. It has been widely used in various fields, such as allergy and autoimmunity research, blood banking, and cancer research. The major advantages of using an RIA are that the test can be performed at very low cost, and it can be performed in a variety of samples, ranging from fluids and sera to tissues and organs. It is also very efficient and has been extensively used in clinical settings for the detection and analysis of immunological assays.
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/1770
In a RIA, an antibody is added to a plate of liquid antigens and then the antigen-antibody complex is added to the interior of the plate. After several hours, the amount of the antibody binding to the antigen-antibody complex is measured by a laboratory analyzer. The higher the concentration of the antibody, the higher the levels of the specific antigens used for the immunoassay. It is also important to note that the use of radioimmunoassay is most useful for in culture dishes.
Competitive Landscape:
Major players operating in the global radioimmunoassay market include, Berthold Technologies GmbH, LLC, Beckman Coulter, Inc., Cisbi, DIAsource ImmunoAssays, Dia Dorin S.p.A., DRG international, Inc., EMD Millipore, Euro Diagnostica, Izotop, IBL Internationa, MP Biomedicals, and PerkinElmer, Inc.
Key Market Drivers:
High prevalence of allergy and asthma is expected to propel growth of the global radioimmunoassay market over the forecast period. For instance, according to the study, ‘Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis’, published in the journal Allergy in February 2020, the prevalence of chronic urticaria was 1.4% in Asian studies, followed by Europe (0.5%) and Northern American (0.1%) studies.
Moreover, R&D in radioactive therapy is also expected to aid in growth of the market. For instance, in October 2021, a study published in Advances in Clinical and Experimental Medicine, reported that the use of a high absorbed dose of 250 grays in patients with Graves disease resulted in high efficacy of radioactive iodine therapy at 1-year follow-up.
Covid-19 Impact Analysis
Globally, as of 8:23pm CEST, 19 October 2021, there have been 240,940,937 confirmed cases of COVID-19, including 4,903,911 deaths, reported to WHO. As of 18 October 2021, a total of 6,545,309,084 vaccine doses have been administered. The emergence of Covid-19 has led to increasing adoption of high sensitivity screening approaches. ELISA has a number of benefits compared to the other immunoassay techniques. It is often preferred because it has high sensitivity and specificity. ELISA also offers more accuracy compared to other techniques such as radioimmunoassay (RIA) tests. Serum-based ELISA can be used with saliva samples and may offer 84.2% sensitivity and 100% specificity in Covid-19 samples.
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/1770
Key Takeaways
- High prevalence of allergy and asthma is expected to propel growth of the global radioimmunoassay market over the forecast period. For instance, according to the study, “Coexistence of allergic rhinitis and asthma in Indian patients: The CARAS survey,” published in the journal Lung India in August 2019, the prevalence of coexisting allergic rhinitis was found to be 65.24%, with the highest prevalence (80%) in the southern regions of India.
- North America is expected to witness significant growth in the global radioimmunoassay market, owing to high prevalence of cancer in the region. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.
- R&D of biomarker-based biosensors has led to limited adoption of radioimmunoassay. For instance, in August 2019, researchers from Indian Institute of Technology Hyderabad developed biomarker-based biosensor device that can detect heart disease with high speed, sensitivity, and reliability.
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837